“Whenever we have seen a change of management like this, it has worked positively for shareholders. Look at what happened in JB Chemicals, and even then UniChem. All the acquisitions which have taken place in the pharma industry have been very positive for both the acquirer as well as the acquired c…

4+1 stocks that Dipan Mehta would keep in his 5-year-plus basket

JB Chemicals & Pharmaceuticals on Wednesday received approval from the US health regulator to market a generic product, used to treat mood disorders, in the American market. The company’s product is the generic version of Pfizer’s Sinequan capsules which are indicated for the treatment of anxiety, d…

JB Chemicals gets USFDA nod to market generic medication

Double-digit growth in the domestic and international formulations segments helped JB Chemicals clock in robust numbers for the April-June quarter.

JB Chemicals scales 52-week high on 35% surge in Q1 net profit

Input cost decline not meaningful in recent months.

JB Chemicals - Normalised Growth To Dampen Earnings Flare Up; Downgrade To ‘Reduce’: Yes Securities

JB Chemicals share price target: Jefferies initiated coverage on the stock with a ‘Buy’ rating and a share price target of Rs 2,680, which suggests 10 per cent potential upside over the record high level.

JB Chemicals shares hit record high as Jefferies values stock at 15% premium over Torrent Pharma

Jefferies, which sees a 19% upside potential, says JB Chemicals is one of the fastest-growing domestic pharma company with a dominance in cardiac and gastro therapies

JB Chemicals hits record high as Jefferies initiates coverage with ‘buy’ call

Expect 15% domestic revenue CAGR over FY23-25E led by new launches, line extensions, improving MR productivity & inorganic growth.

JB Chemicals Q4 Results Review - Robust Performance In Domestic Business: Dolat Capital

During the March quarter, total revenue stood at Rs 762.3 crore, up 22 percent driven by strong performance and double-digit growth across all segments.

JB Chemicals and Pharmaceuticals jumps 6% after strong Q4 numbers

JB Chemicals & Pharmaceuticals Ltd. (JB Pharma) reported fourth quarter net profit grew marginally to ₹88 crore from ₹85 crore in the year-earlier period, up 4%.

JB Pharma Q4 net profit rises 4% to ₹88 crore

Having invested about $200 million in four acquisitions in the last 15 months, JB Chemicals & Pharmaceuticals Ltd. (JB Pharma), majority owned by private equity firm KKR, is scouting for more acquisitions to broad base its offerings as well as to grow its ranking in the Indian pharmaceutical sector.

JB Pharma scouts for acquisitions, eyes bigger pie of domestic market

JB Chemicals & Pharmaceuticals: A final decision on this will be taken during the board meeting to be held on 24 May 2023

JB Chemicals & Pharmaceuticals to consider sub-division of equity shares

The creamy layer - amongst the top performing stocks

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets a range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs).